Template:Amiodarone adverse effects: Difference between revisions
GregArmani (talk | contribs) No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
**More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone. | **More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone. | ||
*[[Amiodarone Pulmonary Toxicity]] | *[[Amiodarone Pulmonary Toxicity]] | ||
*Hyperpigmentation rash[[File:Amiodarone_hyperpigmentation.jpg|thumbnail]] | |||
Revision as of 20:00, 18 February 2016
- Bradycardia
- Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation.
- Prolonged QT
- Thyrotoxicosis[1]
- Between 5-20% of patients treated with amiodarone have thyrotoxicosis (higher in areas of iodine deficiency)
- Iodine-induced hyperthyroidism
- It is thought that the iodine load may unmask hyperthyroidism in patients with multinodular goiter and subclinical Graves’ disease
- Drug-induced destructive thyroiditis
- More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone.
- Amiodarone Pulmonary Toxicity
- Hyperpigmentation rash
- ↑ Rosen's 8th Edition
